Is HYPE at risk of falling to $0?Is HYPE at risk of falling to $0?

Hyperliquid (HYPE) Plunges by 11% Weekly: Further Losses on the Way?

2026/02/25 00:10
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

HYPE, the native token of the decentralized exchange Hyperliquid, has performed quite poorly lately, coinciding with the red wave sweeping through the entire crypto sector.

The token has been the subject of numerous price predictions, with some analysts envisioning additional declines in the short term.

Where is the Bottom?

Currently, HYPE is worth roughly $26, representing an 11% weekly loss and a 56% collapse from its all-time high of almost $60 registered in mid-September last year.

The popular market observer Ali Martinez analyzed the asset’s recent performance and concluded that it is breaking out of a certain triangle formation, risking a further plunge to as low as $20. Sjuul | AltCryptoGems also envisioned a deeper pullback ahead.

Nebraskangooner appears to be the biggest pessimist. He claimed HYPE has been rejected at a key resistance level, forecasting the eventual collapse to zero.

HYPE’s recent exchange netflow reinforces the bearish scenario. Over the last few days, inflows have slightly surpassed outflows, suggesting that some investors have moved away from self-custody and shifted their holdings to centralized platforms. This doesn’t necessarily mean they intend to cash out, but in many cases, such transfers do precede selling activity.

HYPE Exchange NetflowHYPE Exchange Netflow, Source: CoinGlass

How About a Rebound?

The optimists, who forecast that Hyperliquid’s native token could rally substantially in the near future, are just as vocal. X user HYPEconimst suggested that the possible path ahead is a sweep to $27.5, a reclaim of the $30.5 zone, and a pump to $45.5.

The analyst, who goes by the name ryandcrypto on the social media platform, argued that the asset’s price will not plunge below $20 “easily” and “would probably take BTC going well below $60K.”

For their part, TraderSZ envisioned significant volatility ahead and an eventual ascent above $36 in the coming months.

HYPE’s Relative Strength Index (RSI) also hints that a resurgence might be on the way. The technical analysis tool shows whether the asset is overbought or oversold by measuring the speed and magnitude of recent price changes. It runs from 0 to 100, where ratios around and below 30 indicate a rally could be incoming, while anything above 70 is considered bearish territory. As of this writing, the RSI stands just north of the bullish zone.

HYPE RSIHYPE RSI, Source: TradingView

The post Hyperliquid (HYPE) Plunges by 11% Weekly: Further Losses on the Way? appeared first on CryptoPotato.

Market Opportunity
Hyperliquid Logo
Hyperliquid Price(HYPE)
$30.73
$30.73$30.73
+2.84%
USD
Hyperliquid (HYPE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09